Table 6 Current ongoing early phase I/II trials with RET inhibitors
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
RET Inhibitors | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
Pralsetinib (BLU-667) | RET inhibitor | NCT03037385 (1/2) | Monotherapy | RET altered solid tumors including NSCLC |
Selpercatinib (Loxo-292) | RET, VEGFR1, VEGFR3 Inhibitor | NCT03157128 (1/2) | Monotherapy | RET altered solid tumors including NSCLC |
TPX-0046 | RET/SRC Inhibitor | NCT04161391 (1/2) | Monotherapy | RET altered solid tumors including NSCLC |
BOS172738 | RET inhibitor | NCT03780517 (1) | Monotherapy | RET altered solid tumors including NSCLC |